Developing a 90-day vaginal ring that could prevent HIV infection, other sexually transmitted infections and pregnancy, and conducting behavioral studies to understand user-focused factors and promote adoption and use of this technology.
Building and strengthening networks for girl-centered programming that builds protective health, economic, cognitive, and social assets of the most off-track adolescent girls; implementing tools, conducting workshops, introducing technologies, and documenting experiences.
Participating in the scientific committee of the HIV Prevention Clinical Trials Network focused on socio-behavioral sciences to assess research priorities; designing study concepts, protocols, and data-collection instruments; enhancing collaboration; and addressing issues in research ethics.
Establishing potential biomarkers for use in household surveys as an easy and cost-effective approach for verifying assessments of contraceptive use and ultimately tracking progress toward increasing access to sexual and reproductive health services.
Determining immunologic changes in the female genital tract and systemic changes among women initiating progestin-only contraceptives, and evaluating the role of the vaginal microenvironment as a potential modifiable risk-factor for changes in HIV susceptibility.
Modeling multiscale population and urbanization projections at national, state and spatial levels consistent with climate change scenarios for an integrated project on land, energy, and water system in the United States.
Developing an integrated database of settlement-level census records, enabling researchers to understand the complex history of urbanization in India and to estimate levels of environmental risks for urban and rural populations.
Advancing the development of a microarray patch delivering cabotegravir for prevention of HIV infection for up to 4 weeks of protection.
Testing a novel male contraceptive gel containing Nestorone and testosterone applied daily by the male partner in a global Phase 2 clinical trial evaluating the efficacy, safety and acceptability of the gel over a period of 52 weeks.
Developing a non-hormonal on-demand fast dissolving vaginal insert with a window of protection lasting 12 hours that could prevent HIV, other sexually transmitted infections, and pregnancy.